EISAI INC. / AEs / Ames / Pediatric Cancers Eisai Inc. / /
Country
Japan / /
Event
FDA Phase / /
Facility
National Cancer Institute / Institute Common Toxicity Criteria / /
IndustryTerm
natural product / cardiovascular systems / /
MedicalCondition
et al. Nat Rev Cancer / Cancers / tumor / ovarian cancer / cancer / histiocytic lymphoma / NSCLC / hypospermia/aspermia / adult cancer / human tumor / prostate cancers / advanced solid tumors / refractory tumors / soft tissue sarcoma / solid tumors / human cancer / neutropenia / Leukopenia Thrombocytopenia Pancytopenia CTC / bladder cancer / pancreatic cancers / melanoma / fatigue / metastatic breast cancer / rat chronic study / pediatric tumor / non-small cell lung cancer / Stable disease / pediatric cancers / promyelocytic leukemia / hypersensitivity / neutropenia / febrile neutropenia / heavily pretreated breast cancer / head and neck cancer / prostate cancer / human breast cancer / established human cancer / breast cancer / mouse lymphoma mutagenesis assay / pancreatic cancer / /
MedicalTreatment
Premedication / chemotherapies / /
Organization
National Cancer Institute / FDA Pediatric ODAC Subcommittee / Oncology Drugs Advisory Committee / European Medicines Agency / Pharmaceuticals and Medical Devices Agency / Medical Devices Agency / U.S. Food and Drug Administration / Japanese NDA / Pediatric Oncology Subcommittee / /
Position
physician / /
Product
paclitaxel / ketoconazole / CYP3A4 / /
Technology
pharmacokinetics / pharmacodynamics / drug development / apoptosis / /
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived